Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWN12088 DDI with Pirfenidone or Nintedanib
NCT04888715Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bersiporocin in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of Pirfenidone and DWN12088, Area Under the Curve (AUC) of Pirfenidone and DWN12088 and 2 more. Started Jul 2021; status: completed.
02
Drugs
bersiporocin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04888715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888715.